Wealthspire Advisors (Maryland)’s Lipocine LPCN Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2	Closed	–	–	2238
2017 Q1	$0	Buy	+2	New	+$130	﹤0.01%	1978

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s LPCN Position: Q2 2017 in Review

Wealthspire Advisors (Maryland) sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 2 shares.

Wealthspire Advisors (Maryland) first reported a position in LPCN in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

Wealthspire Advisors (Maryland) reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 2 Lipocine shares in Q2 2017.
Wealthspire Advisors (Maryland) first reported a position in Lipocine in Q1 2017 and held it in 1 quarter.
Wealthspire Advisors (Maryland)'s Lipocine position peaked at $0 in Q1 2017.
42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2017, filed 9 Aug 2017.